P I Industries Ltd Q3 FY2026 Concall Summary

Key Takeaways

• Cycle bottoming, recovery promised: Management sees the global AgChem down cycle approaching its latter phase and expects sequential improvement from Q4 FY26, though product pricing remains soft and the recovery call is a bet, not yet visible in numbers.
• Pharma platform doubled, but momentum is cooling: The pharma CRDMO business grew 50% YoY, yet near-term conversion is slowing as biotech funding tightens and geopolitical uncertainty lengthens decision cycles.
• Pharma investment is burning ₹75-80 crore/quarter: Management frames this as deliberate investment for a long-gestation business, not a loss to be cut, and draws a parallel to its contract manufacturing business that took a decade before inflecting.
• Working capital stretched to 139 days: Trade working capital days nearly doubled YoY as PI accommodated partner needs; management expects normalization when the market does, but no timeline is given.
• What to watch next quarter: Whether the promised Q4 sequential volume recovery materializes, the pace of working capital improvement, and any concrete FY27 guidance when the year closes.

AgChem Cycle & Demand Recovery

• Where the cycle sits: The global crop protection market is in the latter phase of a prolonged down cycle, with distributor destocking, soft commodity prices and elevated interest rates all weighing. Channel inventories are gradually normalizing and in-season buying has begun to improve, but product pricing remains soft, especially for generics.
• Rabi season paradox: Rabi sowing progressed well and is ahead of last year on healthy soil moisture and high reservoir storage, yet demand for key agrochemicals stayed muted because elevated channel inventories, adverse weather and lower crop prices overwhelmed the acreage tailwind.
• Exports moderated: AgChem exports softened in line with overall demand, inventory levels of many key products and resulting customer supply schedules.
• Domestic hit by farmer caution: The domestic business was mainly impacted by lower farmer demand for high-value products, though a strong product portfolio and new launches provided some offset.
• The recovery call: Management expects sequential improvement beginning Q4 FY26, with volume growth from Q4 and growth momentum building into FY27 as industry conditions stabilize and new products ramp up. This is a bet on normalization, not a forecast backed by order visibility.

Singhal: "The global crop protection market is approaching the latter phase of a prolonged down cycle, driven by the distributor destocking, adverse weather conditions in certain regions, soft commodity prices and elevated interest rates."

Pharma Platform: Growth, Investment & The Long Bet

• 50% YoY growth, but caution ahead: The pharma platform delivered 50% year-on-year growth driven by deepening relationships with biotech and big pharma innovators. However, near-term momentum moderated due to global biotech funding constraints and ongoing geopolitical uncertainties that are lengthening decision cycles and slowing conversion of select opportunities.
• The ₹75-80 crore/quarter burn: Current EBITDA losses of ₹75-80 crore per quarter in the pharma CRDMO business are characterized by management as investments for the future, not losses of the present. The analogy drawn is to PI's contract manufacturing business, which took a decade before the hockey-stick effect kicked in.
• New customer adds continue: Several new customers were onboarded over the last 12 months, including strategic accounts and big pharma customers, even as the funding environment tightened.
• Contingent consideration write-back: Net profit included exceptional income from a write-back of contingent consideration of ₹126 crore in pharma, partly offset by ₹20.9 crore in provisioning for retirement benefits under the New Labour Code. Management stated the renegotiation reflects no change in strategy and that the business is on strong footing.
• Top-5 CRDMO ambition is a long-gestation play: Management acknowledged this is a long-gestation business currently in the same phase as PI's contract manufacturing was before its inflection, with no timeline offered for when the investment phase yields to profitability.

Singhal: "So, to put in 1 line, look at these as investments for the future and not as losses of present."

New Molecules & Innovation Pipeline

• Pioxaniliprole, India's first NCE: The first new chemical entity from India is under registration in India, with extensive on-field demonstrations launched. Management expects registration within the next financial year, calling it a landmark in Indian history and the first Indian innovation in AgChem.
• Biologicals scaling toward a global franchise: PI is progressing peptide-based technology platforms, with regulatory milestones including approval of Harpin αβ in India and ongoing filings in the U.S. and Latin America. Management sees this as creating a new play in the industry.
• Harpin αβ launch imminent: Approved in India, with launch expected in the next quarter. Domestic biologicals regulatory issues are getting sorted, and management believes Q4 should put those in the past.
• New product launches in domestic: Three new herbicides (Alcor, Comet, Fixit) and one insecticide (Uranus) were launched this year, with two more products expected by the close of FY26.
• PI Mitra Kisan app: A direct-to-farmer mobile app was launched offering crop advisory, product guidance and loyalty benefits, a channel play aimed at farmer engagement.

Singhal: "Within the next financial year, we should be achieving the registration. So that means a landmark in Indian history and the first Indian innovation in Ag-chem."

Plant Healthcare & New Verticals

• Plant healthcare distribution build-out: In Brazil, PI expanded from 2 distributors last year to 33 distributors, with more than 400 farmers testing products and trials showing an almost more than 80% win rate. In Mexico, more than 28 distributors are now active. In the U.S., a distribution network is being set up for the entire Midwest.
• Product launches in the Americas: Two new products were launched in Brazil and two in Mexico. A disease control product received approval in California, the largest U.S. market for that product. A nematode management product is awaiting U.S. approval, expected sometime this month.
• Electronic chemicals gaining traction: New customers were added from Japan and Europe for high-end specialty technology development products. A couple of products have been commercialized, and 4-5 molecules are expected to go for commercialization this year, targeting semiconductor and high-end electronics applications with global innovator customers only.
• Third multipurpose plant added: PI expanded from two to three multipurpose plants, with the third plant servicing specialty and electronic chemicals verticals.

Margins, Working Capital & Balance Sheet

• Gross margin supported by mix: Gross margin expansion was supported by favorable product mix and cost discipline. Management reiterated its long-term gross margin guidance of 50% to 52%, while declining to give a sustainable margin number due to product and business mix variability.
• Price realization soft, raw material costs also down: Industry-wide price realization has softened, but raw material costs have also come down. PI's strategic focus is managing gross margins through portfolio management, technology and a market-to-create-value approach, without confirming or denying specific price compression impact.
• Working capital stretched to 139 days: Trade working capital days increased from 68 to 139 days YoY, reflecting accommodation of partner needs in the current global scenario. Management says this is still much better than industry benchmark norms and expects improvement as market scenarios normalize, but no timeline is given.
• Contract assets expected to reduce by year-end: Management expects contract assets to reduce by year-end but declined to give a specific number, citing dependence on customer shipments, timelines and asset mixes.
• Exceptional items: Net profit included a ₹126 crore write-back of contingent consideration in pharma, partly offset by ₹20.9 crore in provisioning for retirement benefits under the New Labour Code.
• CAPEX for FY27: Approximately ₹500-600 crore is planned, with proper guidance to follow after Board approval next quarter. Pharma intermediate plant CAPEX plans will also be announced next quarter.

CSM Business & Order Book

• CSM not struggling, per management: When an analyst characterized the CSM business as having struggled, management pushed back, stating it was in line with expectations and that positive traction and green shoots are already visible. The business is expected to turn positive in FY27.
• Order book at \$1.2 billion: When an analyst noted it had been some quarters since the order book number was disclosed and asked if it had declined, management stated they have been regularly sharing it and gave the \$1.2 billion figure.
• New client ramp-up question redirected: When asked for line of sight on meaningful ramp-up from new CSM relationships, management redirected to existing long-term relationships with large European and American customers rather than addressing new client ramp-up specifically.

Singhal: "So let me first clarify we are not struggling, number one. It was in line with expectation what we see."

Guidance & Commitments

Key Metrics